GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » PAVmed Inc (NAS:PAVM) » Definitions » Equity-to-Asset
中文

PAVmed (PAVmed) Equity-to-Asset : -1.63 (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is PAVmed Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. PAVmed's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-53.83 Mil. PAVmed's Total Assets for the quarter that ended in Dec. 2023 was $33.12 Mil. Therefore, PAVmed's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was -1.63.

The historical rank and industry rank for PAVmed's Equity-to-Asset or its related term are showing as below:

PAVM' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.74   Med: -0.23   Max: 0.94
Current: -1.63

During the past 10 years, the highest Equity to Asset Ratio of PAVmed was 0.94. The lowest was -1.74. And the median was -0.23.

PAVM's Equity-to-Asset is ranked worse than
97.01% of 870 companies
in the Medical Devices & Instruments industry
Industry Median: 0.65 vs PAVM: -1.63

PAVmed Equity-to-Asset Historical Data

The historical data trend for PAVmed's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PAVmed Equity-to-Asset Chart

PAVmed Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.53 0.10 0.71 -0.18 -1.63

PAVmed Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.18 -0.34 -0.59 -1.03 -1.63

Competitive Comparison of PAVmed's Equity-to-Asset

For the Medical Devices subindustry, PAVmed's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PAVmed's Equity-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, PAVmed's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where PAVmed's Equity-to-Asset falls into.



PAVmed Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

PAVmed's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=-53.831/33.119
=-1.63

PAVmed's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=-53.831/33.119
=-1.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PAVmed  (NAS:PAVM) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


PAVmed Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of PAVmed's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


PAVmed (PAVmed) Business Description

Traded in Other Exchanges
N/A
Address
360 Madison Avenue, 25th Floor, New York, NY, USA, 10017
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The Company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard and the Veris Cancer Care Platform.
Executives
Michael J Glennon director 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
Michael Adam Gordon officer: General Counsel ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Shaun O'neil officer: Chief Operating Officer ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
James L Cox director 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
Debra White director C/O PAVMED INC., ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Ronald M Sparks director 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
Brian J. Deguzman officer: Chief Medical Officer 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
Dennis M Mcgrath officer: President & CFO C/O PAVMED INC., ONE GRAND CENTRAL PLACE, STE. 4600, NEW YORK NY 10165
Lishan Aklog director, 10 percent owner, officer: Chairman and CEO 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10171
Joan B Harvey director ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Timothy E Baxter director ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Matthew Sirovich 10 percent owner C/O SCOPIA MANAGEMENT INC, 450 SEVENTH AVENUE, 43RD FLOOR, NEW YORK NY 10123
Ira Scott Greenspan director 888 SEVENTH AVENUE, 9TH FLOOR, NEW YORK NY 10106
David S. Battleman director C/O TRUENORTH LIFESCIENCES, 348 WEST 57TH STREET, #226, NEW YORK NY 10019
Joshua R Lamstein director 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170